Diamyd Medical AB
- Address
- P. O. Box 7349
Sponsor Overview
Specializations
Type 1 diabetes mellitus
Diamyd Medical AB focuses its clinical research on Type 1 diabetes, with studies centered on preserving beta cell function and supporting glycemic control in people with recent diagnosis or elevated disease risk.
- Recent-onset Type 1 diabetes
- Preservation of insulin production
- Beta cell function
- Glycemic control
The sponsor’s work includes adolescents and adults with HLA DR3-DQ2 and GAD65 antibodies, reflecting a strong interest in immune-defined subgroups within autoimmune diabetes.
Autoimmune risk and early disease stages
Another key area is intervention in individuals at increased risk for Type 1 diabetes, including children and adolescents in Stage 1 and Stage 2 disease with multiple islet autoantibodies.
- Stage 1 Type 1 diabetes
- Stage 2 Type 1 diabetes
- Multiple islet autoantibodies
- Genetic susceptibility markers
These studies reflect interest in early immune-mediated diabetes before full clinical onset, with attention to genetically defined populations carrying the DR3-DQ2 haplotype.
Immune-targeted diabetes therapy
Diamyd Medical AB is engaged in research on antigen-specific immunotherapy for autoimmune diabetes, with a therapeutic focus on modulating the immune response linked to GAD65.
- GAD65-related autoimmunity
- Immune modulation
- Autoimmune diabetes
- Antigen-specific treatment
The clinical program spans both disease preservation in newly diagnosed patients and prevention-oriented studies in individuals at heightened genetic and immunologic risk.
Pediatric and adolescent endocrinology
The sponsor also has a clear interest in pediatric and adolescent endocrinology, particularly in children and teenagers with inherited susceptibility to Type 1 diabetes.
- Children at risk of Type 1 diabetes
- Adolescent diabetes care
- Early autoimmune screening
- Insulin-secreting cell preservation
Research activity extends across multiple sites in several countries, supporting clinical investigation in age groups where early immune intervention may be especially relevant.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Diamyd (Recombinant Human Glutamate Decarboxylase 2) and Colecalciferol in Preserving Beta Cell Function in HLA DR3-DQ2 Positive Type 1 Diabetes |  Czechia Estonia Germany Hungary Poland Spain Sweden The Netherlands | Not Recruiting |
| Evaluation of Intralymphatic Administration of Recombinant Human Glutamate Decarboxylase 2 in HLA DR3-DQ2 Positive Individuals at Risk for Type 1 Diabetes | Sweden | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 42 sites across their trial portfolio.
Therapeutic Focus
- 1.Metabolism2 trials38 other sponsors
Partnered Research Centres
42 centres- Address
- Albert Schweitzerplaats 25, 3318 AT Dordrecht
- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Autovia Del Sur S/n, 35017 Las Palmas de Gran Canaria
- Address
- Blaak 6, 3011 TA Rotterdam
- Address
- Breite Strasse 41, 13187 Berlin
- Address
- Heuserstr. 2, 47051 Duisburg
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Diamyd Medical AB.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.